In Vitro Inhibition of MAP Kinase (ERK1/ERK2) Activity by Phosphorylated Glia Maturation Factor (GMF)

Citations Over Time

Abstract

We report that recombinant glia maturation factor (GMF), a 17-kDa brain protein, inhibits the activity of mitogen-activated protein (MAP) kinase in the test tube assay, in particular the ERK1/ERK2 isoforms. A preliminary phosphorylation of GMF by protein kinase A (PKA) dramatically increases its inhibitory effect by over 600-fold (Ki approximately 3 nM), making it the most potent MAP kinase inhibitor ever reported. Immunoprecipitation of GMF from cell extracts using its specific antibody coprecipitates ERK (and vice versa), suggesting the association of the two proteins in the cell. The inhibitory effect of PKA-phosphorylated GMF is specific, as it does not suppress the activity of cdc2 kinase, another proline-directed kinase. Nor does it inhibit MAP kinase kinase (MEK) and MAP kinase-activated protein (MAPKAP) kinase-2, the two enzymes immediately upstream and downstream, respectively, of ERK. Of the other three enzymes that can phosphorylate GMF, only p90 ribosomal S6 kinase (RSK) enhances the inhibitory function of GMF on ERK; protein kinase C (PKC) and casein kinase II (CKII) are without effect. The inhibition of ERK by PKA-phosphorylated GMF suggests that GMF could be one of the mediators of the suppressive effect of the PKA pathway on the MAP kinase pathway. On the other hand, that RSK-phosphorylated GMF also inhibits ERK implies a negative feedback loop in the regulation of MAP kinase activity.

Related Papers

• → Analysis of conditions affecting auto-phosphorylation of human kinases during expression in bacteria(2011)38 cited
• → Roles of mammalian sterile 20‐like kinase 2‐dependent phosphorylations of Mps one binder 1B in the activation of nuclear Dbf2‐related kinases(2009)21 cited
• → c-Myc transactivation domain-associated kinases: Questionable role for map kinases in c-Myc phosphorylation(1999)26 cited
• → Supplemental Figure 6: UAB30 did not alter expression or phosphorylation of kinases. from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies(2023)
• → Supplemental Figure 6: UAB30 did not alter expression or phosphorylation of kinases. from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies(2023)